Table 5.
Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast after stratification by body mass index (BMI).
| IGFBP-2 (µIU/mL) |
Co/Ca | Model 1 ORa | Model 2 ORb | Co/Ca | Model 3 ORc |
|---|---|---|---|---|---|
| Normal BMI (<25 kg/m2) | |||||
| Q1 | 8/9 | 1.0Ref. | 1.0Ref. | 8/8 | 1.0Ref. |
| Q2 | 17/18 | 0.97 (0.29–3.18) | 1.27 (0.36–4.51) | 16/18 | 1.50 (0.40–5.61) |
| Q3 | 18/28 | 1.36 (0.42–4.41) | 1.99 (0.55–7.26) | 18/28 | 2.49 (0.65–7.22) |
| Q4 | 36/34 | 0.79 (0.25–2.46) | 1.52 (0.42–5.52) | 36/34 | 1.37 (0.37–4.99) |
| Trend | 0.42 | 0.72 | 0.89 | ||
| Overweight/obese (≥25 kg/m2) | |||||
| Q1 | 60/68 | 1.0Ref. | 1.0Ref. | 55/63 | 1.0Ref. |
| Q2 | 51/51 | 0.89 (0.52–1.52) | 1.19 (0.67–2.14) | 44/46 | 1.22 (0.67–2.25) |
| Q3 | 51/49 | 0.82 (0.48–1.37) | 1.02 (0.57–1.82) | 48/45 | 0.95 (0.53–1.73) |
| Q4 | 32/16 | 0.40 (0.19–0.84) | 0.46 (0.19–1.08) | 32/16 | 0.43 (0.18–1.04) |
| Trend | 0.02 | 0.10 | 0.05 |
aModel 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m2).
bModel 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
cModel 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.